A retrospective study showed that when compared to DPP4is, the use of SGLT2 inhibitors was considerably more protective in T2DM patients against new-onset dementia, but not against new-onset AD (Mui et al., 2021). Here, SLC5A2 is linked to type 2 diabetes mellitus.